GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

James Porter, Nuvalent CEO June 9, 2026 02:39 AM EDTUpdated 03:00 AM DealsPharma GSK to ac­quire Nu­va­lent and its two can­cer drugs un­der FDA re­view for $10.6B Kyle LaHucik Biotech Correspondent GSK is mak­ing one of the largest biotech ac­qui­si­tions in its his­to­ry to gain ac­cess to two ex­per­i­men­tal lung can­cer med­i­cines due for FDA ap­proval … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER